Der Onkologe

, Volume 13, Issue 12, pp 1131–1140 | Cite as

Pulmonale Lymphangiosis carcinomatosa

CME Weiterbildung • Zertifizierte Fortbildung

Zusammenfassung

Lymphangiosis carcinomatosa bezeichnet eine diffuse Durchsetzung des pulmonalen Lymphgefäßsystems durch Tumorzellen, am häufigsten ist sie beim Mammakarzinom. Differenzialdiagnostisch ist sie abzugrenzen von u. a. einem „capillary-leak-syndrome“, einer pulmonalen Stauung nach Antracyclin-Therapie, einer radiogenen Pneumonitis, einer durch Immunsuppression bedingten atypischen Pneumonie und einer kardial bedingten Stauung. Trotz der sehr schlechten Spontanprognose ist ein therapeutischer Nihilismus keinesfalls gerechtfertigt. Neben der supportiven Therapie (Diuretika, Steroide, Theophyllin, Heparin, Analgetika) sollte eine tumorspezifische Behandlung nicht vernachlässigt werden, beispielsweise durch 5-FU (i.v., z. B. bei Mamma-, Magenkarzinom), Anthrazykline (nicht vorbehandeltes Mammakarzinom), Taxane und neue Zytostatika (Vinorelbin, Taxotere, Gemcitabin), Immuntherapeutika bzw. -modulatoren (Herceptin, Erlotinib). Im Falle sensibler Tumoren kommt der spezifischen hormonellen Therapie besondere Bedeutung zu.

Schlüsselwörter

Lungenmetastasierung Pleuritis carcinomatosa  Kerley-Linien  Theophyllin Alveolokapillärer Block 

Pulmonary lymphangiosis carcinomatosis

Abstract

Pulmonary lymphangitis carcinomatosis is a diffuse infiltration of the pulmonary lymph vessel system by tumor cells and is most commonly associated with breast cancer. The main factors for differential diagnosis are capillary leak syndrome, pulmonary hypertension after anthracycline therapy, radiogenic pneumonitis, immunosuppression-linked atypical pneumonia and cardiac-linked hypertension. Despite the poor prognosis a therapeutic nihilism is totally unjustified. In addition to supportive therapy (diuretics, steroids, theophylline, heparin and analgesics) a tumor-specific treatment should not be neglected, for example with 5-FU (iv. for breast and stomach cancer), anthracycline (non-pretreated breast cancer), taxanes and new cytostatic drugs (vinorelbin, Taxotere, gemcitabin), immunotherapeutic agents or immunomodulators (Herceptin, erlotinib). In the case of sensitive tumors, a specific hormonal therapy is also extremely useful.

Keywords

Pulmonary metastases Pleuritis carcinomatosis Kerley lines Theophylline Alveolar capillary block 

Literatur

  1. 1.
    Akesaka K, Nakanishi N, Ueda N et al. (2004) A case of carcinomatous lymphangitis of the lungs due to stomach cancer responding to TS-1. Gan To Kagaku Ryoho 31: 233–235PubMedGoogle Scholar
  2. 2.
    Akiyama Y, Kondo H, Shirono R, Fujii Y (1997) A case of lung adenocarcinoma associated with remarkably high levels of CA 19–9 and lymphangitis carcinomatosa. Gan To Kagaku Ryoho 24: 93–96PubMedGoogle Scholar
  3. 3.
    Baur M, Schlappack O, Jakesz R, Dittrich C (1992) Unterschiedliche Prognose von Patientinnen mit Mammakarzinom mit Pleuritis carcinomatosa und mit pulmonaler Lymphangiosis carcinomatosa. Wien Klin Wochenschr 104: 714–716 PubMedGoogle Scholar
  4. 4.
    Bruce DM, Heys SD, Eremin O (1996) Lymphangitis carcinomatosa: a literature review. J R Coll Surg Edinb 41: 7–13PubMedGoogle Scholar
  5. 5.
    Fabozzi SJ, Schellhammer PF, El-Mahdi AM (1995) Pulmonary metastases from prostate cancer. Cancer 75: 2706–2709 PubMedCrossRefGoogle Scholar
  6. 6.
    Fujita J, Yamagishi Y, Kubo A et al. (1993) Respiratory failure due to pulmonary lymphangitis carcinomatosis. Chest 103: 967–968 PubMedCrossRefGoogle Scholar
  7. 7.
    Green N, Kern W, Levis R et al. (1977) Lymphangitic carcinomatosis of the lung: pathologic, diagnostic and therapeutic considerations. Int J Radiat Oncol Biol Phys 2: 149–153 PubMedGoogle Scholar
  8. 8.
    Goldsmith HS, Bailey HD, Callahan EL, Beattie EJ Jr (1967) Pulmonary lymphangitic metastases from breast carcinoma. Arch Surg 94: 483–488 PubMedGoogle Scholar
  9. 9.
    Hamilton CR, Plowman PN (1987) Prolonged remission of lymphangitis carcinomatosis from breast cancer. Br J Dis Chest 81: 400–403PubMedCrossRefGoogle Scholar
  10. 10.
    Hojo K, Kumasaka Y, Nishiyama S et al. (1992) A case of adenocarcinoma of lung cancer with multiple brain metastasis and lymphangitis carcinomatosa responding well to chemotherapy with carboplatin, etoposide and ifosfamide. Gan To Kagaku Ryoho 19: 2403–2406PubMedGoogle Scholar
  11. 11.
    Honda O, Johkoh T, Ichikado K et al. (1999) Comparison of high resolution CT findings of sarcoidosis, lymphoma, and lymphangitic carcinoma: is there any difference of involved interstitium? J Comput Assist Tomogr 23: 374–379PubMedCrossRefGoogle Scholar
  12. 12.
    Kokufu I, Tanei T, Taniguchi H et al. (2002) A case of effective paclitaxel therapy for adriamycin resistant metastatic breast cancer with brain metastases. Gan To Kagaku Ryoho 29: 585–588PubMedGoogle Scholar
  13. 13.
    Levy H, Horak DA, Lewis MI (1988) The value of bronchial washings and bronchoalveolar lavage in the diagnosis of lymphangitic carcinomatosis. Chest 94: 1028–1032PubMedCrossRefGoogle Scholar
  14. 14.
    Lower EE, Baughman RP (1992) Pulmonary lymphangitic metastasis from breast cancer. Lymphocytic alveolitis is associated with favorable prognosis. Chest 102: 1113–1117 PubMedCrossRefGoogle Scholar
  15. 15.
    Mestitz H, Pierce RJ, Holmes PW (1989) Intrathoracic manifestations of disseminated prostatic adenocarcinoma. Respir Med 83: 161–166 PubMedCrossRefGoogle Scholar
  16. 16.
    Miseria S, Torresi U, Menichetti ET et al. (1991) Lymphangitic carcinomas of the lung as presentation of prostatic cancer. A case report. Tumori 77: 86–89 PubMedGoogle Scholar
  17. 17.
    Mizuiri H, Yoshida K, Shimizu K et al. (2004) Weekly paclitaxel therapy is useful for gastric carcinoma as second-line chemotherapy. Gan To Kagaku Ryoho 31: 2043–2046 PubMedGoogle Scholar
  18. 18.
    Ninomiya J, Horiguchi J, Koibuchi Y et al. (2003) Long-term suppression of lymphangitic lung metastasis from breast cancer using biweekly docetaxel: a case report. Breast Cancer 10: 361–365PubMedCrossRefGoogle Scholar
  19. 19.
    Oyama K, Fushida S, Taniguchi K et al. (1999) A case report: modified PMUE therapy might be effective for advanced gastric carcinoma with pulmonary carcinomatous lymphangitis. Gan To Kagaku Ryoho 26: 691–695 PubMedGoogle Scholar
  20. 20.
    Rehbock B, Hieckel HG (2004) Diagnostik der pulmonalen Lymphangiosis carcinomatosa. Radiologe 44: 465–471PubMedCrossRefGoogle Scholar
  21. 21.
    Schulze W (1973) Geschwülste der Bronchien, Lunge und Pleura. In: Diethelm L, Olsson O, Strnad F et al. (Hrsg) Handbuch der Medizinischen Radiologie. Bd. 4c. Springer, Berlin Heidelberg New YorkGoogle Scholar
  22. 22.
    Schwarz MI, Waddell LC, Dombeck DH et al. (1969) Prolonged survival in lymphangitic carcinomatosis. Ann Intern Med 71: 779–783 PubMedGoogle Scholar
  23. 23.
    Shure D, Conforti JF (2000) Tissue Procurement: Bronchoscopic Techniques. In: Pass HI, Mitchell JB, Johnson DH et al. (eds) Lung Cancer. Principles and Practice. 2nd edn. Lippincott Williams and Wilkins Philadelphia Baltimore New York London, pp 579–590Google Scholar
  24. 24.
    Stein MG, Mayo J, Müller N (1987) Pulmonary lymphangitic spread of carcinoma: Appearance on CT scans. Radiology 162: 371–375PubMedGoogle Scholar
  25. 25.
    Takahashi K, Miyagawa K, Mitachi Y et al. (2003) A case of gastric cancer with metastasis to cervical lymph nodes and pulmonary lymphangitis carcinomatosa responding to neoadjuvant chemotherapy with TS-1 and CDDP. Gan To Kagaku Ryoho 30: 685–689PubMedGoogle Scholar
  26. 26.
    Watanabe T, Kawabata H, Takase I et al. (2003) A case of advanced gastric cancer with lymphangitis carcinomatosa of the lung, successfully treated with paclitaxel and TS-1. Gan To Kagaku Ryoho 30: 849–853PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2007

Authors and Affiliations

  1. 1.Klinik für Innere MedizinKlinikum DuisburgDuisburgDeutschland
  2. 2.Institut für Diagnostische und Interventionelle Radiologie Klinikum Niederberg VelbertVelbertDeutschland

Personalised recommendations